DK2827899T3 - Polysaccharidantigen-glycolipid-konjugatvacciner - Google Patents

Polysaccharidantigen-glycolipid-konjugatvacciner Download PDF

Info

Publication number
DK2827899T3
DK2827899T3 DK13710422.0T DK13710422T DK2827899T3 DK 2827899 T3 DK2827899 T3 DK 2827899T3 DK 13710422 T DK13710422 T DK 13710422T DK 2827899 T3 DK2827899 T3 DK 2827899T3
Authority
DK
Denmark
Prior art keywords
carbohydrate
antigen
xaa
virus
acid
Prior art date
Application number
DK13710422.0T
Other languages
English (en)
Inventor
Marco Cavallari
Pierre Stallforth
Peter H Seeberger
Libero Gennaro De
Original Assignee
Max Planck Ges Zur Förderung Der Wissenschaften E V
Universitätsspital Basel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2012/002277 external-priority patent/WO2013178236A1/en
Application filed by Max Planck Ges Zur Förderung Der Wissenschaften E V, Universitätsspital Basel filed Critical Max Planck Ges Zur Förderung Der Wissenschaften E V
Application granted granted Critical
Publication of DK2827899T3 publication Critical patent/DK2827899T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092Streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087Polysaccharides; Lipopolysaccharides [LPS]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/62Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Claims (15)

1. Forbindelse med den almene formel (I):
(l) hvor A betegner et kulhydratantigen med 1 til 10.000 kulhydratmonomerer, og kulhydratantigenet tilhører klassen af polysaccharider, hvor kulhydratmonomererne i kulhydratantigenet eventuelt er modificeret til at bære amid-, car-bonat-, carbamat-, carbonyl-, thiocarbonyl-, carboxy-, thiocarboxy-, ester-, thioester, ether-, epoxy-, hydroxyalkyl-, alkylenyl-, phenylen-, alkenyl-, imino-, imid-, isourea-, thiocarbamat-, thiourea- og/eller ureadele, p er antallet af rester -L-CH-CA, som er bundet til kulhydratantigen A, og p er et heltal defineret som følger: p er 1 eller 2 hvis u er 1 p er 1,2, 3 eller 4 hvis u er 2 p er 1,2, 3, 4, 5 eller 6 hvis u er 3 p er 1,2, 3, 4, 5, 6, 7 eller 8 hvis u er 4 1 ^ p ^ 10 hvis 5 ^ u ^ 10 2 ^ p ^ 50 hvis 11 < u ^ 100 20 ^ p ^ 200 hvis 101 < u ^ 1000 50 ^ p ^ 400 hvis 1001 < u ^ 10000 u er antallet af kulhydratmonomerer i kulhydratantigenet A L betegner -L1-L2-, -L2-, -L2-L3- eller -L1-L2-L3-; L1 betegner en af følgende rester:
hvor x er et heltal fra 1 til 60; S " s-s-· Y betegner en binding, -NH-,^ -CeHi2', -C7H14-, -CeHi6'» WHr.' CH(CH3)-C2H4-, -CH2-CH(CH3)-CHr, -C2H4-CH(CH3)-, -CH2-C[(CH3)2]-> C[(CH3)2]-CH2-, -CH(CH3)-CH(CH3)-, -0[(C2H5)(CH3)]-, -CH(C3H7)-, -(CH2-CH2-0)n-CH2-CH2-, -CO-CH2-, -CO-C2H4-, -CO-C3H6-, -CO-C4H8-, -CO-C5H10-, -CO-C6Hi2-, -CO-C7H14-, -CO-C8Hi6-, -CO-C9His-, -CO-Ci0H20-, -CO-CH(CH3)-, -CO-C[(CH3)2]-, -CO-CH2-CH(CH3)-, -CO-CH(CH3)-CH2-, -co-CH(CH3)-C2H4-, -CO-CH2-CH(CH3)-CH2-, -CO-C2H4-CH(CH3)-, -co-ch2-C[(CH3)2]-, -CO-C[(CH3)2]-CH2-, -CO-CH(CH3)-CH(CH3)-, -co- 0[(02Η5)(0Η3)]-, -CO-CH(C3H7)-, -C0-(CH2-CH2-0)n-CH2-CH2-; n betegner et heltal fra 1 til 60; L3 betegner -CO-, -O-CO-, -NH-CO-, -NH(C=NH)-, -S02-, -0-S02-, -NH-, -NH-CO-CH2-; CH betegner et monosaccharid, et disaccharid eller et trisaccharid; CA beteaner
R* og R# uafhængigt af hinanden betegner en lineær eller forgrenet eller cyklisk, substitueret eller usubstitueret, mættet eller umættet carbonrest bestående af 1 til 30 carbonatomer; og tautomerer og farmaceutisk acceptable salte deraf.
2. Forbindelse ifølge krav 1 med den almene formel (II):
(il) hvor A, L og p har de betydninger, der er defineret i krav 1; R1, R2, R3 uafhængigt af hinanden betegner: -H, -OH, -OCH3, -OC2H5, -OC3H7, -0-S02-CH3, -0-S02-C2H5, -O-SO2-C3H7, -0-C00CH3, -NHCOCHs, -NH2; R* og R# uafhængigt af hinanden betegner: -CH3, -(CH2)rCH3, -CH(OH)-(CH2)s-CH3, -CH=CH-CH3j -CH=CH-(CH2)t-CH3, -CH(OH)-(CH2)v-CH(CH3)2, -CH(OH)-(CH2)w-CH(CH3)-CH2-CH3, -(CH2)a- CH=CH-(CH2)b-CH3, -(CH2)c-CH=CH-(CH2)d-CH=CH-(CH2)e-CH3, -(CH2)r CH=CH-(CH2)g-CH=CH-(CH2)h-CH=CH-(CH2)rCH3, -(CH2)j-CH=CH-(CH2)k-CH=CH-(CH2)i-CH=CH-(CH2)o-CH=CH-(CH2)q-CH3, hvor a, b, c, d, e, f, g, h, i, j, k, I, o, q er heltal fra 1 til 26, forudsat at: (a+b) ^ 27; (c+d+e) ^ 25; (f+g+h+i) ^ 23; (j+k+l+o+q) < 21; og hvor r er et heltal fra 1 til 29, s er et heltal fra 1 til 28, t er et heltal fra 1 til 27, v er et heltal fra 1 til 26, w er et heltal fra 1 til 26.
3. Forbindelse ifølge krav 1 med den almene formel (XIV):
(XIV) hvor A, L, R*, R# og p har de betydninger, der er defineret i krav 1.
4. Forbindelse ifølge et hvilket som helst af kravene 1 - 3, hvor kulhydratmo nomererne i kulhydratantigenet tilhører gruppen af kulhydrater omfattende: a-D-ribopyranose, α-D-arabinopyranose, a-D-xylopyranose, a-D-lyxopyranose, α-D-allopyranose, a-D-altropyranose, α-D-glucopyranose, a-D-mannpyranose, a-D-glucopyranose, α-D-idopyranose, a-D-galactopyranose, α-D-talopyranose, a-D-psicopyranose, α-D-fructopyranose, a-D- sorbopyranose, α-D-tagatopyranose, a-D-ribofuranose, α-D-arabinofuranose, a-D-xylofuranose, α-D-lyxofuranose, a-D-Allofuranose, α-D-Altrofuranose, a-D-Glucofuranose, a-D-Mannofuranose, α-D-gulofuranose, a-D-idofuranose, α-D-galactof uranose, a-D-talof uranose, α-D-psicof uranose, a-D- fructofuranose, a-D-sorbofuranose, α-D-tagatofuranose, a-D-xylulofuranose, α-D-ribulofuranose, a-D-threofuranose, α-D-rhamnopyranose, a-D- erythrofuranose, α-D-glucosamin, a-D-glucopyranuronsyre, β-D-ribopyranose, β-D-arabinopyranose, β-D-xylopyranose, β-D-lyxopyranose, β-D-allopyranose, β-D-altropyranose, β-D-glucopyranose, β-D-mannpyranose, β-D-glucopyranose, β-D-idopyranose, β-D-galactopyranose, β-D- talopyranose, β-D-psicopyranose, β-D-fructopyranose, β-D-sorbopyranose, β-D-tagatopy ranose, β-D-ribofuranose, β-D-arabinofuranose, β-D- xylofuranose, β-D-lyxofuranose, β-D-rhamnopyranose, β-D-allofuranose, β-D-altrofuranose, β-D-glucofuranose, β-D-mannofuranose, β-D-gulofuranose, β-D-idofuranose, β-D-galactofuranose, β-D-talofuranose, β-D-psicofuranose, β-D-fructof uranose, β-D-sorbofuranose, β-D-tagatof uranose, β-D- xylulofuranose, β-D-ribulofuranose, β-D-threofuranose, β-D-erythrofuranose, β-D-glucosamin, β-D-glucopyranuronsyre, α-L-ribopyranose, a-L- arabinopyranose, a-L-xylopyranose, a-L-lyxopyranose, α-L-allopyranose, a-L-altropyranose, a-L-glucopyranose, α-L-mannpyranose, a-L-glucopyranose, α-L-idopyranose, a-L-galactopyranose, α-L-talopyranose, a-L-psicopyranose, α-L-fructopyranose, a-L-sorbopyranose, α-L-tagatopyranose, a-L- rhamnopyranose, a-L-ribofuranose, α-L-arabinofuranose, a-L-xylofuranose, α-L-lyxofuranose, a-L-Allofuranose, α-L-Altrofuranose, α-L-Glucofuranose, a-L-Mannofuranose, a-L-gulofuranose, α-L-idofuranose, a-L-galactofuranose, α-L-talofuranose, a-L-psicofuranose, α-L-fructofuranose, a-L-sorbofuranose, α-L-tagatofuranose, a-L-xylulofuranose, α-L-ribulofuranose, a-L- threofuranose, a-L-erythrofuranose, α-L-glucosamin, a-L- glucopyranuronsyre, β-L-ribopyranose, β-L-arabinopyranose, β-L- xylopyranose, β-L-lyxopyranose, β-L-allopyranose, β-L-altropyranose, β-L-glucopyranose, β-L-mannpyranose, β-L-glucopyranose, β-L-idopyranose, β-L-galactopyranose, β-L-talopyranose, β-L-psicopyranose, β-L- fructopyranose, β-L-sorbopyranose, β-L-tagatopyranose, β-L-ribofuranose, β-L-arabinofuranose, β-L-xylofuranose, β-L-lyxofuranose, β-L-allofuranose, β-L-altrofuranose, β-L-glucofuranose, β-L-mannofuranose, β-L-gulofuranose, β-L-idofuranose, β-L-galactofuranose, β-L-talofuranose, β-L-psicofuranose, β-L-fructofuranose, β-L-sorbofuranose, β-L-tagatofu ranose, β-L- xylulofuranose, β-L-ribulofuranose, β-L-threofuranose, β-L-erythrofuranose, β-L-glucosamin, β-L-glucopyranuronsyre, β-L-rhamnopyranose, eller N- eller O-substituerede derivater af neuraminsyre med følgende formel:
hvor Z betegner -NH2, -NHAc eller -OH. ;
5. Forbindelse ifølge et hvilket som helst af kravene 1 - 4, hvor kulhydratmonomererne i CH-delen tilhører gruppen af kulhydrater omfattende: a-D-ribopyranose, α-D-arabinopyranose, a-D-xylopyranose, a-D- lyxopyranose, α-D-allopyranose, a-D-altropyranose, α-D-glucopyranose, a-D-mannpyranose, a-D-glucopyranose, α-D-idopyranose, a-D-galactopyranose, α-D-talopyranose, a-D-psicopyranose, α-D-fructopyranose, a-D- sorbopyranose, α-D-tagatopyranose, a-D-ribofuranose, α-D-arabinofuranose, a-D-xylofuranose, α-D-lyxofuranose, a-D-Allofuranose, α-D-Altrofuranose, a-D-Glucofuranose, a-D-Mannofuranose, α-D-gulofuranose, a-D-idofuranose, α-D-galactof uranose, a-D-talof uranose, α-D-psicof uranose, a-D- fructofuranose, a-D-sorbofuranose, α-D-tagatofuranose, a-D-xylulofuranose, α-D-ribulofuranose, a-D-threofuranose, α-D-erythrofuranose, a-D-glucosamin, α-D-glucopyranuronsyre, a-D-rhamnopyranose, β-D-ribopyranose, β-D-arabinopyranose, β-D-xylopyranose, β-D-lyxopyranose, β-D-allopyranose, β-D-altropyranose, β-D-glucopyranose, β-D-mannpyranose, β-D-glucopyranose, β-D-idopyranose, β-D-galactopyranose, β-D-talopyranose, β-D-psicopyranose, β-D-fructopyranose, β-D-sorbopyranose, β-D- tagatopyranose, β-D-ribofuranose, β-D-arabinofuranose, β-D-xylofuranose, β-D-lyxofuranose, β-D-allofuranose, β-D-altrofuranose, β-D-glucofuranose, β-D-mannofuranose, β-D-gulofuranose, β-D-idofuranose, β-D-galactofuranose, β-D-talof uranose, β-D-psicofuranose, P-D-fructof uranose, β-D- sorbofuranose, β-D-tagatofuranose, β-D-xylulofuranose, β-D-ribulofuranose, β-D-threof uranose, β-D-eryth rof uranose, β-D-rhamnopyranose, β-D- glucosamin, β-D-glucopyranuronsyre, α-L-ribopyranose, a-L-arabinopyranose, a-L-xylopyranose, a-L-lyxopyranose, α-L-allopyranose, a-L-altropyranose, a-L-glucopyranose, α-L-mannpyranose, a-L-glucopyranose, α-L-idopyranose, a-L-galactopyranose, α-L-talopyranose, a-L-psicopyranose, α-L-fructopyranose, a-L-sorbopyranose, α-L-tagatopyranose, a-L- ribofuranose, α-L-arabinofuranose, a-L-xylofuranose, α-L-lyxofuranose, a-L-Allofuranose, α-L-Altrofuranose, a-L-Glucofuranose, α-L-Mannofuranose, a-L-gulofuranose, a-L-idofuranose, α-L-galactofuranose, a-L-talofuranose, a-L-psicofuranose, α-L-fructofuranose, a-L-sorbofuranose, α-L-tagatofuranose, a-L-xylulofuranose, a-L-ribulofuranose, α-L-rhamnopyranose a-L- threof uranose, α-L-eryth rof uranose, α-L-glucosamin, α-L- glucopyranuronsyre, β-L-ribopyranose, β-L-arabinopyranose, β-L-xylopyranose, β-L-lyxopyranose, β-L-allopyranose, β-L-altropyranose, β-L-glucopyranose, β-L-mannpyranose, β-L-glucopyranose, β-L-idopyranose, β-L-galactopyranose, β-L-talopyranose, β-L-psicopyranose, β-L- fructopyranose, β-L-sorbopyranose, β-L-tagatopyranose, β-L-ribofuranose, β-L-arabinofuranose, β-L-xylofuranose, β-L-lyxofuranose, β-L-allofuranose, β-L-altrofuranose, β-L-glucofuranose, β-L-mannofuranose, β-L-gulofuranose, β-L-idofuranose, β-L-galactofuranose, β-L-talofuranose, β-L-psicofuranose, β-L-fructofuranose, β-L-sorbofuranose, β-L-tagatof uranose, β-L- xylulofuranose, β-L-ribulofuranose, β-L-threofuranose, β-L-erythrofuranose, β-L-glucosamin, β-L-glucopyranuronsyre, β-L-rhamnopyranose.
6. Forbindelse ifølge et hvilket som helst af kravene 1 - 5, hvor saccharidan-tigenet A er et baterielt kapsel-saccharid, et saccharid af viralt glycoprotein, et saccharidantigen af sporozoer eller parasitter, et saccharidantigen af patogene svampe eller et saccharidantigen, som er specifikt for cancerceller.
7. Forbindelse ifølge et hvilket som helst af kravene 1 - 6 til anvendelse som farmaceutisk aktivt stof i medicin eller til anvendelse ved vaccination mod infektionssygdomme.
8. Forbindelse ifølge krav 7, hvor infektionssygdommen er forårsaget af et patogen valgt fra gruppen omfattende: Allochromatium vinosum, Acinetobacter baumanii, Bacillus anthracis, Campylobacter jejuni, Clostridium spp., Citrobacter spp., Escherichia coli, Entero-bacter spp., Enterococcus faecalis., Enterococcus faecium, Francisella tula-rensis, Haemophilus influenzae, Helicobacter pylori, Klebsiella spp., Listeria monocytogenes, Moraxella catharralis, Mycobacterium tuberculosis, Neisseria meningitidis, Neisseria gonorrhoeae, Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa, Salmonella spp., Serratia spp., Shigella spp., Stenotrophomonas maltophilia, Staphylococcus aureus, Staphylococcus epi-dermidis, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Yersinia pestis, Yersinia enterocolitica, influenzavirus, human immundefektvirus ("HIV"), herpes simplex virus ("HSV", type 1 eller 2), human papillomavirus ("HPV", type 16 eller 18), hu- man cytomegalovirus ("HCMV") eller human hepatitis B- eller C-virus ("HBV", type B; "HCV", type C).
9. Forbindelse ifølge krav 6, hvor det bakterielle kapsel-saccharid tilhører bakterier udvalgt blandt: Allochromatium vinosum, Acinetobacter baumanii, Bacillus anthracis, Campylobacter jejuni, Clostridium spp., Citrobacter spp., Escherichia coli, Entero-bacter spp., Enterococcus faecalis., Enterococcus faecium, Francisella tula-rensis, Haemophilus influenzae, Helicobacter pylori, Klebsiella spp., Listeria monocytogenes, Moraxella catharralis, Mycobacterium tuberculosis, Neisseria meningitidis, Neisseria gonorrhoeae, Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa, Salmonella spp., Serratia spp., Shigella spp., Stenotrophomonas maltophilia, Staphylococcus aureus, Staphylococcus epi-dermidis, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Yersinia pestis og Yersinia enterocolitica.
10. Forbindelse ifølge krav 6, hvor saccharidet af virale glycoproteiner tilhører vira udvalgt blandt: Adenovira, Ebolavirus, Epstein-Barr-virus, Flavivirus, FSME-virus, Influenzavirus, Hanta-virus, human immundefektvirus ("HIV"), herpes simplex virus ("HSV", type 1 eller 2), human herpes virus 6 (HHV-6), human papillomavirus ("HPV", type 16 eller 18), human cytomegalovirus ("HCMV"), human hepatitis B- eller C-virus ("HBV", type B; "HCV", type C), Lassavirus, Lyssavirus (EBL 1 eller EBL 2), Marburgvirus, Norovirus, Parvovirus B19, Pestvirus, Poliovirus, Rhinovirus, Rotavira, SARS-associeret Coronavirus, Varicella-Zoster-virus.
11. Forbindelse ifølge krav 6, hvor saccharidantigenet af sporozoer eller parasitter tilhører sporozoer eller parasitter udvalgt blandt: Babesia, Balantidium, Besnoitia, Blastocystis, Coccidia, Cryptosporidium, Cytauxzoon, Cyclospora, Dientamoeba, Eimeria, Entamoeba, Enterocyto-zoon, Enzephalitozoon, Eperythrozoon, Giardia, Hammondia, Isospora, Lei-shmania, Microsporidia, Naegleria, Plasmodium, Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Plasmodium knowlesi, Pneumocystis, Schistosoma, Sarcocystis, Theileria, Trichinella, Toxoplasma, Trichomonas, Trypanosoma, Unicaria, Cestoda, Dipylidium, Dranunculus, Echinococcus, Fasciola, Fasciolopsis, Taenia, Ancylostoma, Ascaris, Brugia, Enterobius, Loa loa, Mansonella, Necator, Oncocerca, Strongyloides, Strongylus, Toxocara, Toxascaris, Trichuris eller Wucheria.
12. Forbindelse ifølge krav 6, hvor saccharidantigenet af svampe tilhører svampe udvalgt blandt: Trichophyton mentagrophytes, Trichophyton rubrum, Trichophyton interdigi-tale, T. schonleinii, T. verrucosum, T. violaceum, T. tonsurans, Trichophyton spp., M. canis, Candida albicans, C. guillermondii, C. krusei, C. parapsilosis, C. tropicalis, C. glabrata, Candida spp., Microsporum spp., Microsporum canis, Microsporum audonii, Microsporum gypseum, M. ferrugineum, Trichos-porum beigelii, Trichosporum inkiin, Aspergillus niger, Alternaria, Acremoni-um, Fusarium eller Scopulariopsis.
13. Forbindelse ifølge krav 6, hvor saccharidantigenet, som er specifikt for cancerceller, tilhører gruppen af cancere udvalgt blandt: blærecancer, brystcancer, colon- og rektalcancer, endometriecancer, nyrecancer (renalcellecancer), leukæmi, lungecancermelanom, Non-Hodgkin lym-fom, pancreascancer, prostatacancer, cancer i skjoldbruskkirtlen.
14. Forbindelse ifølge et hvilket som helst af kravene 1 - 6, hvor det gennemsnitlige forhold mellem kulhydratantigenet A og glycolipid (L-CH-CA) er mellem 1:4 og 1:100 (n/n).
15. Vaccineformulering omfattende en forbindelse eller en blanding af forskellige forbindelser ifølge et hvilket som helst af kravene 1-14.
DK13710422.0T 2012-03-19 2013-03-19 Polysaccharidantigen-glycolipid-konjugatvacciner DK2827899T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2012054848 2012-03-19
PCT/EP2012/002277 WO2013178236A1 (en) 2012-05-26 2012-05-26 Carbohydrate-glycolipid conjugate vaccines
PCT/EP2013/055719 WO2013139803A1 (en) 2012-03-19 2013-03-19 Carbohydrate-glycolipid conjugate vaccines

Publications (1)

Publication Number Publication Date
DK2827899T3 true DK2827899T3 (da) 2015-10-26

Family

ID=47901120

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13710422.0T DK2827899T3 (da) 2012-03-19 2013-03-19 Polysaccharidantigen-glycolipid-konjugatvacciner

Country Status (23)

Country Link
US (1) US10588962B2 (da)
EP (1) EP2827899B1 (da)
JP (2) JP5933106B2 (da)
KR (1) KR101675657B1 (da)
CN (1) CN104321079A (da)
AR (1) AR090386A1 (da)
AU (1) AU2013237497B2 (da)
BR (1) BR112014023193A2 (da)
CA (1) CA2866978C (da)
CY (1) CY1116706T1 (da)
DK (1) DK2827899T3 (da)
ES (1) ES2551599T3 (da)
HK (1) HK1205682A1 (da)
HU (1) HUE028144T2 (da)
IL (1) IL234604A (da)
MX (1) MX337202B (da)
PL (1) PL2827899T3 (da)
PT (1) PT2827899E (da)
RU (1) RU2649009C2 (da)
SG (1) SG11201405646TA (da)
SI (1) SI2827899T1 (da)
TW (1) TWI633112B (da)
WO (1) WO2013139803A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2851092A1 (en) 2013-09-18 2015-03-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Protein and peptide-free synthetic vaccines against streptococcus pneumoniae type 3
WO2016152980A1 (ja) * 2015-03-24 2016-09-29 国立大学法人岐阜大学 オリゴヌクレオチド誘導体及びそれを用いたオリゴヌクレオチド構築物並びにそれらの製造方法
CN106565800B (zh) * 2015-10-08 2019-08-13 中国人民解放军第二军医大学 三糖对甲氧基苯酚苷类化合物及其制备方法
TWI732825B (zh) * 2016-05-20 2021-07-11 日商王子控股股份有限公司 圖案形成用定向自組裝組成物、圖案形成用定向自組裝組成物用單體及圖案形成方法
CN106620682A (zh) * 2017-01-19 2017-05-10 华中师范大学 一种脂质体疫苗制剂及其用途和生产IgG抗体的方法
MX2020002556A (es) * 2017-09-07 2020-07-13 Merck Sharp & Dohme Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora.
CN107955082B (zh) * 2017-12-11 2019-05-10 江南大学 幽门螺旋杆菌脂多糖外核心八糖的制备方法
CN111760020B (zh) * 2020-05-18 2023-05-26 广州中医药大学(广州中医药研究院) 一种缀合物及其制备方法和应用
CN111760021B (zh) * 2020-05-18 2023-06-16 广州中医药大学(广州中医药研究院) 一种含有α-半乳糖神经酰胺类似物与糖抗原的缀合物及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
FI20010118A (fi) * 2001-01-19 2002-07-20 Carbion Oy Uudet helicobacter pylori reseptorit ja niiden käyttö
CA2453880A1 (en) * 2001-07-25 2003-02-06 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
US8273357B2 (en) * 2004-07-16 2012-09-25 Massachusetts Institute Of Technology Antigen-carbohydrate conjugates
WO2006026389A2 (en) 2004-08-27 2006-03-09 Albert Einstein College Of Medicine Of Yeshiva University Ceramide derivatives as modulators of immunity and autoimmunity
US8022043B2 (en) * 2004-08-27 2011-09-20 Albert Einstein College Of Medicine Of Yeshiva University Ceramide derivatives as modulators of immunity and autoimmunity
GB0419846D0 (en) * 2004-09-07 2004-10-13 Chiron Srl Vaccine adjuvants for saccharides
US7923013B2 (en) * 2004-12-28 2011-04-12 The Rockefeller University Glycolipids and analogues thereof as antigens for NKT cells
WO2007051004A2 (en) * 2005-10-28 2007-05-03 The Brigham And Women's Hospital, Inc. Conjugate vaccines for non-proteinaceous antigens
US8697659B2 (en) 2007-10-12 2014-04-15 Luigi Panza Analogues of glycolipids useful as immunoadjuvants
EP2058011A1 (en) * 2007-11-07 2009-05-13 Wittycell Nkt cell activating gycolipids covalently bound antigens and/or drug
WO2010083728A1 (en) * 2009-01-23 2010-07-29 Dapeng Zhou Nanoparticle formulated glycolipid antigens for immunotherapy
US8455565B2 (en) 2011-05-18 2013-06-04 3M Innovative Properties Company Disulfide monomers comprising ethylenically unsaturated groups suitable for dental compositions

Also Published As

Publication number Publication date
CN104321079A (zh) 2015-01-28
BR112014023193A2 (pt) 2017-08-01
RU2649009C2 (ru) 2018-03-29
IL234604A (en) 2016-03-31
EP2827899B1 (en) 2015-08-05
EP2827899A1 (en) 2015-01-28
MX337202B (es) 2016-02-17
CA2866978C (en) 2019-01-29
CY1116706T1 (el) 2017-03-15
PL2827899T3 (pl) 2015-12-31
KR20140138996A (ko) 2014-12-04
JP2015514067A (ja) 2015-05-18
SG11201405646TA (en) 2014-10-30
WO2013139803A1 (en) 2013-09-26
KR101675657B1 (ko) 2016-11-11
JP6235648B2 (ja) 2017-11-22
MX2014011242A (es) 2015-03-09
TWI633112B (zh) 2018-08-21
US10588962B2 (en) 2020-03-17
AU2013237497B2 (en) 2016-05-12
RU2014142043A (ru) 2016-05-20
SI2827899T1 (sl) 2015-11-30
TW201343662A (zh) 2013-11-01
ES2551599T3 (es) 2015-11-20
JP2016183166A (ja) 2016-10-20
HK1205682A1 (en) 2015-12-24
AR090386A1 (es) 2014-11-05
PT2827899E (pt) 2015-11-18
HUE028144T2 (en) 2016-11-28
AU2013237497A1 (en) 2014-10-02
CA2866978A1 (en) 2013-09-26
JP5933106B2 (ja) 2016-06-08
US20150238597A1 (en) 2015-08-27

Similar Documents

Publication Publication Date Title
DK2827899T3 (da) Polysaccharidantigen-glycolipid-konjugatvacciner
US10973910B1 (en) Neoglycoconjugates as vaccines and therapeutic tools
CA2961694A1 (en) Vaccines against streptococcus pneumoniae serotype 8
JP7277459B2 (ja) クレブシエラ ニューモニエ(Klebsiella pneumoniae)に対するワクチン
JP2021518435A (ja) 治療用ツールとしての精密なグリココンジュゲート
KR102250099B1 (ko) 스트렙토코커스 뉴모니에 1형에 대한 합성 백신
WO2013178236A1 (en) Carbohydrate-glycolipid conjugate vaccines
JP2021504438A (ja) クレブシエラ ニューモニエ(Klebsiella pneumoniae)に対するワクチン
KR102549847B1 (ko) 헤모필루스 인플루엔자 타입 b에 대항하는 백신으로서 안정한 가수분해-내성 합성 폴리리보실리비톨포스페이트 유도체
US20230346905A1 (en) Pentavalent vaccine against neisseria meningitidis comprising a synthetic men a antigen
WO2022150924A1 (en) Process for the synthesis of reactive carbohydrates including antigen precursors for conjugation with a carrier material